NCT03825718 - A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

December 1, 2020

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

GC007F

GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

Trial Locations (1)

065200

Hebei Yanda Ludaopei Hospital, Sanhe